Hoth Therapeutics, Inc.

NasdaqCM:HOTH Voorraadrapport

Marktkapitalisatie: US$5.9m

Hoth Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Hoth Therapeutics's earnings have been declining at an average annual rate of -6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.

Belangrijke informatie

-6.0%

Groei van de winst

30.8%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie6.0%
Inkomstengroein/a
Rendement op eigen vermogen-79.9%
Nettomargen/a
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Opbrengsten en kosten

Hoe Hoth Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

NasdaqCM:HOTH Opbrengsten, kosten en inkomsten (USD Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 240-753
31 Mar 240-853
31 Dec 230-843
30 Sep 230-1054
30 Jun 230-1055
31 Mar 230-1165
31 Dec 220-1165
30 Sep 220-1165
30 Jun 220-1256
31 Mar 220-1367
31 Dec 210-1478
30 Sep 210-1266
30 Jun 210-1064
31 Mar 210-1064
31 Dec 200-743
30 Sep 200-1074
30 Jun 200-1064
31 Mar 200-953
31 Dec 190-852
30 Sep 190-431
30 Jun 190-321
31 Mar 190-321
31 Dec 180-211
30 Sep 180-321

Kwaliteitswinsten: HOTH is currently unprofitable.

Groeiende winstmarge: HOTH is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: HOTH is unprofitable, and losses have increased over the past 5 years at a rate of 6% per year.

Versnelling van de groei: Unable to compare HOTH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: HOTH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendement op eigen vermogen

Hoge ROE: HOTH has a negative Return on Equity (-79.89%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden